Based on my research, I now have sufficient information to draft the comprehensive legislation document. Let me compile this into the required format.

National Pandemic Preparedness and Response

Current Status

Existing Law: Under section 361 of the Public Health Service Act (42 U.S. Code § 264), the U.S. Secretary of Health and Human Services is authorized to take measures to prevent the entry and spread of communicable diseases from foreign countries into the United States and between states.¹ On December 19, 2006, the Pandemic and All-Hazards Preparedness Act (PAHPA), Public Law No. 109-417, was signed into law by President George W. Bush.² Emergency Use Authorization authority is codified by 21 U.S.C. § 360bbb-3, to allow the use of a drug prior to approval.³
Current Authority: The authority for carrying out these functions on a daily basis has been delegated to the Centers for Disease Control and Prevention (CDC).⁴ The Administration for Strategic Preparedness and Response (ASPR) serves as the principal advisor to the HHS Secretary on issues related to public health and medical emergency preparedness and response. ASPR has operational responsibilities for the advanced research, development and stockpiling of medical countermeasures as well as the coordination of the federal public health and medical response to emergencies and disasters.⁵ The Biomedical Advanced Research and Development Authority (BARDA) is a center within ASPR responsible for the procurement and development of medical countermeasures, principally against bioterrorism and pandemic threats. BARDA was established in 2006 through the Pandemic and All-Hazards Preparedness Act (PAHPA).⁶
Existing Limitations: Decreased and episodic funding from the United States government has stakeholders questioning the true commitment federal lawmakers have for sustaining the nation's preparedness and response capabilities.⁷ CDC's Public Health Emergency Preparedness (PHEP) cooperative agreement, which provides funding and technical assistance to state, local and territorial health departments to support their emergency preparedness, has seen its funding decrease over the past two decades. The program's current annual funding of $735 million is far short of the $1 billion recommended by the public health community.⁸

Problem

Specific Harm

The economic toll of the COVID-19 pandemic in the U.S. will reach $14 trillion by the end of 2023.⁹ In the United States, at least 103 million COVID-19 cases have been reported since the pandemic began. The Centers for Disease Control and Prevention (CDC) reports that at least 1.21 million people have officially died of the illness in the U.S.¹⁰ By the end of 2020, the CDC counted 385,676 confirmed U.S. deaths caused by the virus. The weekly death rate peaked soon after, with 25,974 people dying of the virus during the first week of 2021. A total of 463,267 COVID-19 deaths were recorded in 2021, which was the deadliest year for the virus in the U.S.¹¹

In a scenario in which 30% of the US population becomes ill from pandemic influenza, the estimated need for N95 respirators is 3.5 billion. However, the actual supply in the US stockpile was far smaller at 30 million.¹² The $8.5 billion federal repository had long been depleted of personal protective equipment for medical workers. With the pandemic looming, the United States had just 35 million N95 masks on hand, the vast majority left over from a single purchase made in 2009.¹³

Who is Affected

Healthcare workers: As of May 2020, 87% of nurses reported having to reuse a single-use disposable mask or N95 respirator, and 27% of nurses reported they had been exposed to confirmed COVID-19 patients without wearing appropriate PPE.¹⁴
General population: According to the CDC, over 81 percent of COVID-19 deaths have occurred in those age 65 or older.¹⁵
Economic impact across all sectors: At the height of the pandemic, airline travel fell by nearly 60%, indoor dining by 65% and in-store shopping by 43%.¹⁶

Gaps in Current Law

Stockpile Management: Neither Congress, the Obama White House, nor the subsequent Trump administration moved to substantially refill the stockpile — leaving a depleted stash of the N95 masks that would prove essential in protecting health care workers in the fight against COVID. "You can't be prepared if you're not funded to be prepared."¹⁷
Domestic Manufacturing Dependency: Analysis of trade data shows that the US is the world's largest importer of face masks, eye protection, and medical gloves, making it highly vulnerable to disruptions in exports of medical supplies.¹⁸
State-Federal Coordination: Doctors and nurses were forced to reuse the same N95 masks for a week, even though they're designed to be discarded after seeing each patient. This federal failure of the supply chain forced states to bid against other states, as well as against the federal government, for items like medical-grade face masks and disposable gloves.¹⁹

Accountability Failures

The government approved a plan in 2015 to buy tens of millions of N95 respirators but the masks repeatedly lost out in the competition for funding over the years leading up to the pandemic.²⁰
Federal officials were given about $700 million of the $1 billion they requested from Congress.²¹
National biosurveillance capabilities are threatened by shortfalls in state and local financial resources. Limits in state budgets make it difficult for agencies to maintain information systems and staff solely with local resources.²²

Proposed Reform

Primary Policy Change

Restructure pandemic preparedness authorities to create a unified command structure with clear operational versus advisory roles, mandatory stockpile maintenance requirements, and expedited authorization mechanisms for public health emergencies.

New Requirements

1. CDC Operational/Advisory Role Clarification

CDC shall maintain primary authority for disease surveillance, epidemiological investigation, and public health guidance
ASPR shall maintain operational authority for emergency response coordination, medical countermeasure deployment, and healthcare surge coordination
GAO shall conduct biennial audits of role delineation effectiveness

2. Strategic National Stockpile Modernization

Mandatory maintenance of minimum stockpile levels based on pandemic modeling scenarios
Required domestic manufacturing capacity for critical PPE and medical countermeasures equal to 90-day surge requirements
Real-time inventory management system with automatic rotation protocols
The Strategic National Stockpile received $965 million in the FY 2025 budget, building on a 58% increase in funding over the last four years.²³ This Act authorizes annual appropriations at recommended level of $1.2 billion adjusted for inflation, with GAO annual reporting on any shortfall

3. State-Federal Coordination Framework

Codify clear authority boundaries between federal, state, and local jurisdictions during declared public health emergencies
CDC's Public Health Emergency Preparedness (PHEP) Cooperative Agreement provides funding to 50 states, 4 cities, and 8 U.S. territories and freely associated states.²⁴ Authorize restoration to inflation-adjusted FY2006 levels ($1 billion annually recommended)
Expedited Congressional notification and authorization request upon HHS Secretary declaration of public health emergency, with GAO monitoring of response funding adequacy

4. Biosurveillance Infrastructure Enhancement

Implement national electronic laboratory reporting infrastructure with estimated costs of $25 million to plan the system, $25 million to build state public health laboratory information systems where needed, $600 million to implement the system, and $100 million per year to operate and maintain it.²⁵
Mandate real-time data sharing between CDC, state health departments, and healthcare facilities
Integration with existing healthcare IT systems

5. Medical Countermeasure Development (BARDA Reform)

BARDA received $2.09 billion which includes $50 million to continue their investments in the research and development of threat-agnostic countermeasures.²⁶ Authorize funding at recommended level of $2.5 billion annually
Establish permanent "warm base" manufacturing capacity for rapid vaccine production scale-up
Strengthen Other Transaction Authority (OTA) for expedited contracting during emergencies

6. Healthcare Surge Capacity Requirements

HPP is the primary source of federal funding for health care preparedness and response. HPP provides funding to 62 recipients, including the governments of all 50 states, eight U.S. territories and freely associated states, the District of Columbia.²⁷ Authorize funding at recommended level of $500 million annually
Require healthcare coalitions to maintain documented surge capacity plans verified by ASPR exercises

7. Essential Worker Designation Framework

Codify federal essential worker categories during public health emergencies
Establish priority access to medical countermeasures for designated essential workers
Create standardized cross-state recognition of essential worker credentials

8. Supply Chain Resilience

Medical reshoring trends in the U.S. were catalyzed following the outbreak of COVID-19, which saw a considerable increase in demand for critical medical equipment, including ventilators, testing kits, and personal protective equipment (PPE).²⁸
Mandate domestic or allied-nation sourcing for minimum 50% of critical medical supplies within 5 years
Require supply chain mapping and risk assessment for critical medical products

New Prohibitions

Prohibit diversion of stockpile funding to non-preparedness activities without Congressional notification
Prohibit export of critical medical supplies during declared public health emergencies without ASPR waiver
Prohibit single-source procurement for critical medical countermeasures without documented justification and backup sourcing plan

Enforcement

GAO Authority: GAO shall conduct annual audits of stockpile inventory, expiration dates, and funding compliance
HHS OIG Authority: HHS Office of Inspector General shall investigate waste, fraud, and mismanagement in preparedness programs
Judicial Conference: Coordinate with Judicial Conference on expedited review procedures for emergency procurement challenges
Penalty Structure: Agency heads failing to maintain minimum stockpile levels subject to mandatory Congressional testimony; repeat failures trigger automatic funding remediation from agency discretionary budgets

What Changes

Before

Fragmented authority between CDC, ASPR, FEMA, and HHS with unclear operational boundaries
Boom-and-bust funding cycles: BARDA needs stable preparedness funding, not boom and bust cycles. Congress sends influxes of money when it wants specific outputs: Congress sent $7.65 billion to combat the 2009 swine flu pandemic and has sent $32 billion in additional funds for COVID. However, injections of emergency funds do not provide cost effective outcomes. Medical countermeasure development and procurement require years of sustained funding.²⁹
Stockpile depleted without replenishment mechanisms
State-federal competition for medical supplies during emergencies
Over-reliance on foreign manufacturing for critical medical supplies

After

Unified command structure with CDC (advisory/surveillance) and ASPR (operational response) clearly delineated
Authorization at recommended funding levels indexed to inflation, with GAO annual reporting on shortfalls relative to pandemic modeling requirements
Stockpile maintained at pandemic-ready levels with real-time inventory and mandatory rotation
Pre-negotiated state allocation formulas and federal distribution protocols eliminate bidding wars
Domestic manufacturing capacity for 90-day surge of critical supplies

ROI

Federal Budget Impact (10-Year, CBO-Scoreable)

Costs:

Item	10-Year
Strategic National Stockpile (incremental above baseline)	$2.5B
Biosurveillance Infrastructure Implementation	$0.8B
BARDA Enhanced Funding (incremental)	$4.0B
PHEP Restoration to $1B/year	$2.7B
HPP Enhancement	$2.0B
Domestic Manufacturing Incentives	$3.0B
Contingency (15%)	$2.3B
Total	$17.3B

Savings:

Item	Gross	Capture	Net
Avoided emergency supplemental appropriations (based on COVID response costs)³⁰	$50.0B	30%	$15.0B
Reduced healthcare surge costs from earlier detection	$20.0B	25%	$5.0B
Stockpile efficiency gains from rotation/expiration reduction	$2.0B	70%	$1.4B
Supply chain competition elimination savings	$5.0B	40%	$2.0B
Total			$23.4B

Result: Net +$6.1B · ROI 1.4:1

Societal Benefits

Benefit	Annual	NPV (3%)	NPV (7%)
Reduced mortality (10% reduction in pandemic deaths at $7M VSL)³¹	$84.7B	$722B	$595B
Reduced GDP loss (5% reduction in economic disruption)³²	$70.0B	$597B	$492B
Mental health burden reduction³³	$8.0B	$68B	$56B
Healthcare worker protection	$2.0B	$17B	$14B

Summary

Category	10-Year	Notes
Federal Budget	+$6.1B (1.4:1)	CBO-scoreable; conservative capture rates
Societal	$595B - $722B	NPV at 3-7%; mortality and economic benefits

Confidence: MEDIUM - Federal budget estimates based on historical appropriations patterns and documented COVID response costs. Societal benefits use established VSL methodology but pandemic frequency assumptions carry uncertainty. Harvard economists estimated cumulative financial costs of the COVID-19 pandemic at more than $16 trillion, or roughly 90% of annual GDP of the United States.³⁴ Even modest reductions in future pandemic costs generate substantial returns.

References

Public Health Service Act, 42 U.S.C. § 264 (Section 361)
Pandemic and All-Hazards Preparedness Act, Pub. L. 109-417 (2006)
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3 (Emergency Use Authorization)
HHS, "Who has the authority to enforce isolation and quarantine" (2009)
ASPR, Budget and Funding Overview (2024)
Wikipedia, Biomedical Advanced Research and Development Authority (2024)
Pandemic and All-Hazards Preparedness Act, Congressional Research Service (2023)
Trust for America's Health, "Impact of Chronic Underfunding on America's Public Health System" (August 2024)
USC Schaeffer Center, COVID-19 Economic Cost Study (May 2023)
CDC National Center for Health Statistics, COVID-19 Mortality Data (2024)
Newsweek, "How Many People Have Died from COVID-19?" (December 2024)
Carias et al., PMC, "Contributing factors to personal protective equipment shortages" (2020)
NBC News, "A rare look inside the Strategic National Stockpile" (July 2022)
National Nurses United Survey, PMC (May 2020)
CDC, COVID-19 Age Demographics (2024)
Fortune Well, COVID-19 Economic Impact (May 2023)
PBS FRONTLINE, "Depleted National Stockpile Contributed to COVID PPE Shortage" (October 2020)
PMC, "Contributing factors to personal protective equipment shortages" (2020)
STAT News, "America's broken PPE supply chain must be fixed now" (June 2021)
Wikipedia, Strategic National Stockpile (2024)
NBC News, Strategic National Stockpile Investigation (July 2022)
PMC, "Improving Biosurveillance Systems" (2017)
ASPR, FY 2025 Budget Statement (2024)
CDC, Emergency Preparedness Funding (2024)
Association of Public Health Laboratories, National ELR Infrastructure Cost Estimate (2007)
ASPR, FY 2025 Budget BARDA Allocation (2024)
Federal Register, Hospital Preparedness Program Funding Formula RFI (December 2024)
Thomas Industrial Network, "Reshoring Trends in the Medical Industry" (2025)
Institute for Progress, "Why BARDA Deserves More Funding" (2022)
COVID Money Tracker, Federal Relief Spending Analysis (2024)
JAMA, Cutler & Summers, "The COVID-19 Pandemic and the $16 Trillion Virus" (October 2020)
Congressional Budget Office, COVID-19 Output Gap Projections (2020)
Harvard Gazette, COVID-19 Mental Health Cost Estimates (November 2020)
JAMA Viewpoint, Cutler & Summers Economic Analysis (October 2020)

Change Log

2025-01-19 - Fiscal Flexibility: Converted mandatory funding floors and automatic triggers to authorization language with recommended levels and GAO shortfall reporting. Preserves pandemic preparedness policy signal while maintaining Congressional appropriations authority. Per framework-wide fiscal automaticity audit.
2025-12-08 - Created: Initial draft. Key sources: CDC mortality data, ASPR budget documents, Trust for America's Health underfunding report, JAMA economic analysis, Congressional Research Service PAHPA overview, GAO biosurveillance reports, Strategic National Stockpile investigations.